Latest news with #TetraGraph
Yahoo
26-05-2025
- Business
- Yahoo
Senzime Applauds Announcement of Upcoming European Pediatric Guidelines of Neuromuscular Monitoring
UPPSALA, SE / / May 26, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Lisbon, Portugal - Senzime AB (publ.) welcomes today's pre-announcement of the first pediatric guidelines of quantitative neuromuscular monitoring during anesthesia. The guideline announcement was done at the Euroanaesthesia 2025 (ESAIC) congress in Lisbon with final publication and announcement expected later in 2025, representing a significant update to pediatric anesthesia practice. "Pediatric patients have long been underserved when it comes to neuromuscular monitoring," commented Philip Siberg, CEO of Senzime. "Today's announcements are based on analysis of over 8,000 studies signaling EMG as a recommended monitoring technology in pediatric anesthesia. This represents a pivotal moment for clinicians who want to ensure safety and recovery in the youngest and most vulnerable patients. The announcement further represents a critical step in improving patient safety and presents a substantial market opportunity for our TetraGraph system, a leading EMG-based quantitative train-of-four (TOF) solution."Each year, approximately 10-12 million pediatric major surgeries are performed worldwide with neuromuscular blocking drugs, with around 3 million in the US alone. Research has shown that without proper monitoring, over 40% of pediatric patients experience residual neuromuscular block (rNMB) postoperatively, leading to respiratory complications, airway obstruction, and delayed the well-documented risks of rNMB, pediatric anesthesia has historically relied on qualitative neuromuscular monitoring or no monitoring at all, due to the lack of specialized pediatric solutions. The pre-announced guidelines call for a recommendation of quantitative neuromuscular monitoring, ensuring that paralytic and reversal drugs are properly dosed, and rNMB is TetraGraph® system is the only neuromuscular monitor on the market with a separate and specific FDA-cleared electromyography (EMG) sensor for use on patients from one month old. Unlike legacy neuromuscular monitors, TetraGraph monitors use EMG to accurately analyze the direct effects of paralytic drugs and does not require free-moving muscles, making it ideal for pediatric and tucked-arm cases such as robotic surgical procedures. For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: About Senzime Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at Attachments Senzime applauds announcement of upcoming European pediatric guidelines of neuromuscular monitoring SOURCE: Senzime View the original press release on ACCESS Newswire
Yahoo
13-05-2025
- Business
- Yahoo
Senzime Launches Medical Affairs Division and Education Platform to Drive Transformation in Anesthesia Monitoring
UPPSALA, Sweden and ST. LOUIS, May 13, 2025 /PRNewswire/ -- Senzime, a global leader in precision-based perioperative monitoring solutions, today announced the formation of a new Medical Affairs division and the parallel launch of Senzime Academy—an open-access education platform designed to advance the implementation of guideline-supported neuromuscular monitoring worldwide. "These initiatives aim to drive the next wave of clinical transformation in anesthesia care, as Senzime continues to strengthen our role not only as a device innovator, but as a scientific and educational partner," said Philip Siberg, CEO of Senzime. "Our new Medical Affairs team and educational platform reflect our commitment to partnering with providers to implement evidence-based practices that elevate patient outcomes." Building a Global Clinical CommunitySenzime's new Medical Affairs division will serve as a hub for collaboration with leading academic centers, anesthesia providers, and perioperative teams. Its mission is to translate clinical research into real-world practice, support best-in-class implementation, and elevate global awareness about the ongoing risks of residual neuromuscular block (rNMB). The division is led by Jen Sanders, Director of Clinical and Medical Affairs. Addressing the Real-World Needs of Anesthesia TeamsTo support widespread adoption of neuromuscular monitoring, Senzime Academy offers clinicians on-demand training on quantitative train-of-four (TOF) monitoring and best practices for TetraGraph® use. The digital platform includes video modules, clinical case examples, and implementation guides for both adult and pediatric care settings. Built on 40+ Years of Scientific ResearchSenzime's flagship TetraGraph system is the result of over four decades of neuromuscular monitoring research, translated into a clinically robust, EMG-based platform purpose-built to meet the demands of modern surgery. Its proprietary TOF monitoring technology is clinically evaluated in 19 peer-reviewed publications, making it the most studied EMG system available today. TetraGraph is used in over 3,500 operating rooms worldwide, supporting compliance with best practices outlined by the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC). More information how Senzime's solutions can be used across specialized clinical applications, such as robotic-assisted surgeries, pediatrics, and enhanced recovery after surgery (ERAS), is available at More information about Senzime Academy is available at For further information, please contact:Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: About SenzimeSenzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at View original content to download multimedia: SOURCE Senzime Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-04-2025
- Business
- Yahoo
Interim Report January-March 2025: 94 Percent Growth
UPPSALA, SE / / April 22, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - March 2025 is now available on the company's website Financial information January - March 2025 Net sales amounted to TSEK 23,499 KSEK (12,120), a 94 percent increase. Sales of instruments/other were TSEK 9,237 (4,864), a 90 percent increase. Sales of disposables were TSEK 14,262 (7,256), a 97 percent increase. The gross margin excluding amortization was 65.9 percent (64.3). Operating expenses amounted to TSEK 37,297 (37,441) EBITDA was TSEK -20,839 (-28,546). Profit (loss) after financial items was TSEK -35,522 (-28,719). Earnings per-share were SEK -0.27 (-0.23). Cash and cash equivalents as of March 31, 2025, were TSEK 62,059 (116,856). CEO comment:We have strong momentum. Net sales in Q1 increased by 94 percent to SEK 23.5 million. A quarter with record sales, several new important hospital contracts, product launches, and expansion to meet demand. Deliveries of disposable sensors more than doubled once again. Our new TetraGraph system, introduced in the US during the fourth quarter of 2024, has been very well received by the market. Numerous clinical evaluations conducted at hospitals in the US and Europe have unanimously praised its unique design and how it simplifies and accelerates compliance with the new clinical guidelines for neuromuscular monitoring. During the quarter, we announced several key hospital contracts won through competitive evaluations. This is a direct result of the successful investments we have made in research and development in recent years. In total, we delivered over 440 new TetraGraph systems in the first quarter, compared with just under 900 TetraGraph Classics delivered throughout all of 2024. In mid-March, we also launched the new TetraGraph system in the European market. In just two weeks, we delivered more new systems than we sold TetraGraph Classics in Europe during all of 2024. More launches are planned for the year, with Japan and South Korea next in line. Demand is strong. The success of our business model is especially evident in the sales of disposable sensors, which continue to grow at a triple-digit rate. Utilization of the TetraGraph systems is increasing, and we are continuously winning new customers. The gross margin improved compared to Q1 last year and operating expenses were in line with the previous year despite extensive commercial investments. We will achieve profitability through high utilization of our systems, offer the most user-friendly and innovative solutions, and scale up with the support of smart, industrial partnerships. The pipeline for 2025 is strong, and we continue to see high demand. We have a unique portfolio of solutions that meet market needs. Follow us on our journey toward improved patient safety for millions of patients. Philip Siberg, CEO Uppsala, Sweden, April 2025 For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: Slavoljub Grujicic, CFOPhone: +46 (0) 76 306 60 11, e-mail: About Senzime Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany. Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at . This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-22 08:30 CEST. Attachments Senzime Interim Q1 ENG SOURCE: Senzime View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
17-02-2025
- Business
- Yahoo
Interim report January - December 2024: Our Rapid Growth Journey Continued in 2024 with a 65% Growth Rate
UPPSALA, SWEDEN / / February 17, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB's (publ) interim report for January - December 2024 is now available on the company's website Financial information October - December 2024 • Net sales amounted to TSEK 14,034 (10,850), an increase of 29 percent.• Currency-adjusted net sales increased by 28 percent.• Sales of disposable sensors amounted to TSEK 11,042 (6,647), an increase of 66 percent.• In the USA, net sales increased to TSEK 9,478 (8,300), an increase of 14 percent.• Sales of disposable sensors in the USA amounted to TSEK 7,561 (5,269), an increase of 44 percent.• The gross margin before depreciation amounted to 67.4 percent (70.8).• Operating costs amounted to TSEK 32,970 (43,379).• Operating profit before depreciation amounted to TSEK -18,161 (-34,655).• The result after financial items amounted to TSEK -27,838 (-39,617).• Earnings per share amounted to SEK -0.20 (-0.33).• Cash and cash equivalents as of 12/31/2024 amounted to TSEK 100,941 (151,009). Financial information January - December 2024 • Net sales amounted to TSEK 58,477 (35,754), an increase of 64 percent.• Currency-adjusted net sales increased by 65%• Sales of disposable sensors amounted to TSEK 39,183 (19,526), an increase of 101 percent.• In the USA, net sales increased to TSEK 42,605 (24,742), an increase of 72 percent.• The gross margin before depreciation amounted to 64.4 percent (69.8).• Operating costs amounted to TSEK 144,178 (145,699).• Operating profit before depreciation amounted to TSEK -97,892 (-116,794).• The result after financial items amounted to TSEK -122,780 (-137,159).• Earnings per share amounted to SEK -0.97 (-1.45). Extract from the CEO comment: Our rapid growth journey continued in 2024 with a 65% growth rate Sales in 2024 increased to SEK 58.5 million, representing a growth rate of 65 percent. Single-use sensors accounted for the major increase with sales more than doubling in 2024, a strong confirmation of our business model. More than two-thirds of our sales in 2024 were related to single-use sensors. We delivered 900 TetraGraph systems during the year to leading hospitals worldwide, and the adoption rate is continuously increasing. Our technology is rapidly establishing itself as de facto standard in operating rooms and our systems are now used in over 500 hospitals globally. Despite a significant expansion of our commercial operations in the US, we have kept our total operating costs flat as compared to the year before. The successful October introduction of the next-generation TetraGraph impacted Q4 revenues as expected. The next-generation TetraGraph system was showcased at the annual American ANESTHESIOLOGY 2024 congress, and I am proud to report exceptionally positive feedback from the market. The October introduction impacted Q4 revenues as majority of our ongoing sales processes transitioned to our new system, especially in the US market. We delivered the first FDA cleared units according to plans in December 2024. Shortly after the end of the quarter, we secured several contracts for the new TetraGraph system. These include orders from a major university hospital system in the southeastern US for a total of 79 systems, orders from a leading US university hospital for the first 25 systems, and expansion orders for monitors from the highest-ranked hospital system in the US market. In addition, we secured additional important contracts in Switzerland, as an extension to the wins we already announced in the fourth quarter of 2024. 2024 was another breakthrough year for Senzime. The expansion of our US commercial team and marketing efforts led to significant contract wins and strengthened market share. We secured several of the top 25 healthcare systems in the US, both for adults and children, and we delivered continuously under our first major procurement contract (GPO), in the US. Sales in Japan gained momentum thanks to the successful launch of the first integrated patient monitor module based on our TetraGraph technology through our licensee Fukuda Denshi. In South Korea, sales increased sharply, supported by increased reimbursement for our type of technology and by increased utilization of the installed base of over 300 TetraGraphs in the country. A big thank you to the phenomenal Senzime team and thank you to all the investors who continue to support us. If 2025 continues as it has started, it will certainly be a fantastic year for Senzime. Presentation of the report Senzime invites investors, analysts and press to a webcast presentation of the 2024 report on February 17th at 2 p.m. The presentation will be given by CEO Philip Siberg and after the presentation there will be a question-and-answer session moderated by Klas Palin, analyst at Carnegie Investment Bank. The presentation is in English. Questions to the moderator can be emailed to before 10 a.m. on February 17th. The presentation can be viewed on Senzime's website via the link This press release only contains parts of the full interim report release that is published on Senzime's website: For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: Grujicic, CFOPhone: +46 (0) 76 306 60 11, e-mail: About Senzime Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany. Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at . This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-17 07:30 CET. Attachments Senzime Interim Report Q4 2024 SOURCE: Senzime View the original press release on ACCESS Newswire Sign in to access your portfolio
